Evidence for NQO1 and NQO2 catalyzed reduction of ortho-and para-quinone methides

Free Radical Research

Volumn 47, Issue 12, 2013, Pages 1016-1026

  Kucera, H R ^a   Livingstone, M ^b   Moscoso, C G ^a   Gaikwad, N W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Enzyme kinetics; Mass spectrometry; NQO1; NQO2; ortho quinone methide; Para quinone methide; Substrate binding

Indexed keywords

NRH QUINONE OXIDOREDUCTASE 2; ORTHO CRESOL; OXIDOREDUCTASE; PARA CRESOL; QUINONE DERIVATIVE; QUINONE METHIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ARTICLE; ELECTROPHILICITY; ENZYME INACTIVATION; ENZYME MECHANISM; ENZYME STRUCTURE; ENZYME SUBSTRATE; MOLECULAR DOCKING; TANDEM MASS SPECTROMETRY;

HUMANS; INDOLEQUINONES; MASS SPECTROMETRY; MOLECULAR DYNAMICS SIMULATION; NAD; NAD(P)H DEHYDROGENASE (QUINONE); QUINONE REDUCTASES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84887443979     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.847527     Document Type: Article

References (59)

1. Ostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010; 501: 116-123.
2. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004; 382: 115-144. (Pubitemid 38240788)
3. Iyanagi T. On the mechanisms of one-and two-electron transfer by flavin enzymes. Chem Scr 1987; 27A: 31-36.
4. Leung KKK, Litchfield DW, Shilton BH. Flavin adenine dinucleotide content of quinone reductase 2: Analysis and optimization for structure-function studies. Anal Biochem 2012; 420: 84-89.
5. Dinkova-Kostova AT, Talalay P. Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic Biol Med 2000; 29: 231-240.
6. Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomaki K, et al. NQO1 expression correlates inversely with NFkappaB activation in human breast cancer. Breast Cancer Res Treat 2012; 132: 955-968.
7. Stoehr CG, Nolte E, Wach S, Wieland WF, Hofstaedter F, Hartmann A, Stoehr R. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) P187S polymorphism and prostate cancer risk in caucasians. Int J Mol Sci 2012; 13: 10959-10969.
8. Chen J, Lin Y, Zhang R, Huang ZJ, Pan XG. Contribution of NAD(P)H quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and risk of colorectal adenoma and colorectal cancer in Caucasians: a meta-analysis. Arch Med Res 2012: 43: 58-66.
9. Malik MA, Zargar SA, Mittal B. Role of NQO1 609C> T and NQO2 -3423G > A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis. Mol Biol Rep 2012; 39: 9095-9104.
10. Zhang Y, Wang ZT, Zhong J. Meta-analysis demonstrates that the NAD(P)H: quinone oxidoreductase 1 (NQO1) gene 609 C > T polymorphism is associated with increased gastric cancer risk in Asians. Genet Mol Res 2012; 11: 2328-2337.
11. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 2012; 118: 1856-1867.
12. Patrick BA, Jaiswal AK. Stress-induced NQO1 controls stability of C/EBPalpha against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer. Oncogene 2012; 31: 4362-4371.
13. Dunna NR, Anuradha C, Vure S, Sailaja K, Surekha D, Raghunadharao D, et al. NQO1 * 2 [NAD(P)H: quinone oxidoreductase 1 polymorphism and its influence on acute leukemia risk. Biol Med 2011; 3: 19-25.
14. Zhu H, Li Y. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovasc Toxicol 2012; 12: 39-45.
15. van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur EN, Ross D, et al. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004; 25: 1253-1262. (Pubitemid 39094028)
16. Ramprasath T, Murugan PS, Kalaiarasan E, Gomathi P, Rathinavel A, Selvam GS. Genetic association of Glutathione peroxidase-1 (GPx-1) and NAD(P)H:Quinone Oxidoreductase 1(NQO1) variants and their association of CAD in patients with type-2 diabetes. Mol Cell Biochem 2012; 361: 143-150.
17. Hubackova M, Vaclavikova R, Ehrlichova M, Mrhalova M, Kodet R, Kubackova K, et al. Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer 2012; 130: 338-348.
18. Mandal RK, Nissar K, Mittal RD. Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India. Mol Biol Rep 2012; 39: 11145-11152.
19. Fu Y, Buryanovskyy L, Zhang Z. Quinone reductase 2 is a catechol quinone reductase. J Biol Chem 2008; 283: 23829-23835.
20. Harada S, Tachikawa H, Kawanishi Y. A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia. Psychiatr Genet 2003; 13: 205-209. (Pubitemid 38033105)
21. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, et al. NAD(P)H:quinone oxidoreductase 1 NQO1 ? 2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008; 40: 844-853. (Pubitemid 351913646)
22. Ernster L, Lindberg O. Animal mitochondria. Annu Rev Physiol 1958; 20: 13-42.
23. Liao S, Williams-Ashman HG. Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide. Biochem Biophys Res Commun 1961; 4: 208-213.
24. Long DJ, II, Jaiswal AK. NRH: quinone oxidoreductase2 (NQO2). Chem Biol Interact 2000; 129: 99-112.
25. Nosjean O, Nicolas JP, Klupsch F, Delagrange P, Canet E, Boutin JA. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol 2001; 61: 1369-1379. (Pubitemid 32452352)
26. Jaiswal AK, Burnett P, Adesnik M, McBride OW. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 1990; 29: 1899-1906. (Pubitemid 20074738)
27. Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, et al. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997; 347: 221-228. (Pubitemid 27492792)
28. Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM. Crystal structure of human quinone reductase type 2, a metalloflavoprotein. Biochemistry 1999; 38: 9881-9886.
29. AbuKhader M, Heap J, De Matteis C, Kellam B, Doughty SW, Minton N, Paoli M. Binding of the anticancer prodrug CB1954 to the activating enzyme NQO2 revealed by the crystal structure of their complex. J Med Chem 2005; 48: 7714-7719. (Pubitemid 41698811)
30. Ross D, Siegel D. NAD(P)H: Quinone Oxidoreductase 1 (NQO1, DT-Diaphorase), Functions and pharmacogenetics. In: Helmut S; Lester P, (eds.). Methods in Enzymology. San Diego, CA: Academic Press; 2004. pp. 115-144. (Pubitemid 38240788)
31. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 2005; 7: 463-478. (Pubitemid 41445486)
32. Bianco NR, Chaplin LJ, Montano MM. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem J 2005; 385: 279-287.
33. Gaikwad NW, Rogan EG, Cavalieri EL. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen orthoquinones. Free Radic Biol Med 2007; 43: 1289-1298. (Pubitemid 47429941)
34. Gaikwad NW, Yang L, Rogan EG, Cavalieri EL. Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones. Free Radic Biol Med 2009; 46: 253-262.
35. Gaikwad NW. Metabolomic profiling unravels DNA adducts in human breast that are formed from peroxidase mediated activation of estrogens to quinone methides. PLoS One 2013; 8: e65826.
36. Gaikwad NW, Bodell WJ. Formation of DNA adducts by microsomal and peroxidase activation of p-cresol: role of quinone methide in DNA adduct formation. Chem Biol Interac 2001; 138: 217-229. (Pubitemid 33063637)
37. Gaikwad NW, Bodell WJ. Formation of DNA adducts in HL-60 cells treated with the toluene metabolite p-cresol: a potential biomarker for toluene exposure. Chem Biol Interac 2003; 145: 149-158. (Pubitemid 36398428)
38. Gaikwad NW, Bodell WJ. Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts. Free Radic Biol Med 2012; 52: 340-347.
39. Gaikwad NW. Ultra performance liquid chromatographytandem mass spectrometry method for profiling of steroid metabolome in human tissue. Anal Chem 2013; 85: 4951-4960.
40. Grosdidier A, Zoete V, Michielin O. Fast docking using the CHARMM force field with EADock DSS. J Comput Chem 2011.
41. Grosdidier A, Zoete V, Michielin O. SwissDock, a proteinsmall molecule docking web service based on EADock DSS. Nucleic Acids Res 2011; 39: W270-277.
42. Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, Amzel LM. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci U S A 2000; 97: 3177-3182. (Pubitemid 30183275)
43. National Center for Biotechnology Information. PubChem Compound Database; CID -136328 http://pubchem.ncbi. nlm.nih.gov/summary/summary.cgi?cid=136328 (accessed Feb. 15, 2012).
44. National Center for Biotechnology Information. PubChem Compound Database; CID -13265823 http://pubchem.ncbi.nlm. nih.gov/summary/summary.cgi?cid= 13265823&loc=ec-rcs (accessed Feb. 16, 2012).
45. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-1612.
46. Li R, Bianchet MA, Talalay P, Amzel LM. The threedimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc Natl Acad Sci U S A 1995; 92: 8846-8850.
47. Vella F, Ferry G, Delagrange P, Boutin JA. NRH: quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005; 71: 1-12. (Pubitemid 41715231)
48. Calamini B, Santarsiero BD, Boutin JA, Mesecar AD. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J 2008; 413: 81-91. (Pubitemid 351946864)
49. Bianchet MA, Erdemli SB, Amzel LM. Structure, function, and mechanism of cytosolic quinone reductases. Vitam Horm 2008; 78: 63-84.
50. Liu Y, Rokita SE. Inducible alkylation of DNA by a quinone methide-peptide nucleic acid conjugate. Biochemistry 2012; 51: 1020-1027.
51. Basner JE, Schwartz SD. Donor acceptor distance and protein promoting vibration coupling to hydride transfer: a possible mechanism for kinetic control in isozymes of human lactate dehydrogenase. J Phys Chem B 2003; 108: 444-451.
52. Belinsky M, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993; 12: 103-117. (Pubitemid 23220675)
53. Joseph P, Xie T, Xu Y, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res 1994; 6: 525-532.
54. Jaiswal AK. Human NAD(P)H:quinone oxidoreductase2. Gene structure, activity, and tissue-specific expression. J Biol Chem 1994; 269: 14502-14508.
55. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000; 29: 246-253.
56. Jaiswal AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med 2000; 29: 254-262.
57. Strassburg A, Strassburg CP, Manns MP, Tukey RH. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol 2002; 61: 320-325. (Pubitemid 34112806)
58. Graves PR, Kwiek JJ, Fadden P, Ray R, Hardeman K, Coley AM, et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. M ol Pharmacol 2002; 62: 1364-1372. (Pubitemid 35403831)
59. Zhou Q, Qu Y, Mangrum JB, Wang X. DNA alkylation with N-methylquinolinium quinone methide to N2-dG adducts resulting in extensive stops in primer extension with DNA polymerases and subsequent suppression of GFP expression in A549 cells. Chem Res Toxicol 2011; 24: 402-411.